Literature DB >> 19003198

Modifications of therapeutic proteins: challenges and prospects.

Nigel Jenkins1.   

Abstract

The production of therapeutic proteins is one of the fastest growing sectors of the pharmaceutical industry. However, most proteins used in drug therapy require complex post-translational modifications for efficient secretion, drug efficacy and stability. Common protein modifications include variable glycosylation, misfolding and aggregation, oxidation of methionine, deamidation of asparagine and glutamine, and proteolysis. These modifications not only pose challenges for accurate and consistent bioprocessing, but also may have consequences for the patient in that incorrect modifications or aggregation may lead to an immune response to the protein therapeutic. This review provides examples of analytical and preventative advances that have been devised to meet these challenges, and insights into how further advances can improve the efficiency and safety in manufacturing recombinant proteins.

Entities:  

Year:  2007        PMID: 19003198      PMCID: PMC2267613          DOI: 10.1007/s10616-007-9075-2

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  35 in total

1.  Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response.

Authors:  A Bertolotti; Y Zhang; L M Hendershot; H P Harding; D Ron
Journal:  Nat Cell Biol       Date:  2000-06       Impact factor: 28.824

2.  Stability of human serum albumin during bioprocessing: denaturation and aggregation during processing of albumin paste.

Authors:  J J Lin; J D Meyer; J F Carpenter; M C Manning
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

3.  Characterization of protein aggregation: the case of a therapeutic immunoglobulin.

Authors:  Barthélemy Demeule; M Jayne Lawrence; Alex F Drake; Robert Gurny; Tudor Arvinte
Journal:  Biochim Biophys Acta       Date:  2006-10-27

4.  Determination of protein oxidation by mass spectrometry and method transfer to quality control.

Authors:  Damian Houde; Paivi Kauppinen; Rohin Mhatre; Yelena Lyubarskaya
Journal:  J Chromatogr A       Date:  2006-05-22       Impact factor: 4.759

5.  Commercial interest grows in glycan analysis.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2007-02-01       Impact factor: 54.908

Review 6.  Getting the glycosylation right: implications for the biotechnology industry.

Authors:  N Jenkins; R B Parekh; D C James
Journal:  Nat Biotechnol       Date:  1996-08       Impact factor: 54.908

Review 7.  Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.

Authors:  Paris Roach; James R Woodworth
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms.

Authors:  M Yang; M Butler
Journal:  Biotechnol Prog       Date:  2002 Jan-Feb

9.  In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase.

Authors:  Dale Warnock; Xiaomei Bai; Katie Autote; Johnny Gonzales; Kyle Kinealy; Boxu Yan; Jun Qian; Tom Stevenson; David Zopf; Robert J Bayer
Journal:  Biotechnol Bioeng       Date:  2005-12-30       Impact factor: 4.530

10.  High affinity capture surface for matrix-assisted laser desorption/ionisation compatible protein microarrays.

Authors:  Jens-Oliver Koopmann; Jonathan Blackburn
Journal:  Rapid Commun Mass Spectrom       Date:  2003       Impact factor: 2.419

View more
  27 in total

1.  Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab.

Authors:  Fabienne Courtois; Neeraj J Agrawal; Timothy M Lauer; Bernhardt L Trout
Journal:  MAbs       Date:  2016       Impact factor: 5.857

Review 2.  Human immunoglobulin allotypes: possible implications for immunogenicity.

Authors:  Roy Jefferis; Marie-Paule Lefranc
Journal:  MAbs       Date:  2009 Jul-Aug       Impact factor: 5.857

3.  Modulation of self-association and subsequent fibril formation in an alanine-rich helical polypeptide.

Authors:  Ayben Top; Kristi L Kiick; Christopher J Roberts
Journal:  Biomacromolecules       Date:  2008-05-02       Impact factor: 6.988

4.  Multivariate analysis of the sequence dependence of asparagine deamidation rates in peptides.

Authors:  Andrew A Kosky; Vasumathi Dharmavaram; Gayathri Ratnaswamy; Mark Cornell Manning
Journal:  Pharm Res       Date:  2009-09-09       Impact factor: 4.200

5.  Rational development of a strategy for modifying the aggregatibility of proteins.

Authors:  Zhongping Tan; Shiying Shang; Samuel J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

6.  Optimizing High-Resolution Mass Spectrometry for the Identification of Low-Abundance Post-Translational Modifications of Intact Proteins.

Authors:  Lisa E Kilpatrick; Eric L Kilpatrick
Journal:  J Proteome Res       Date:  2017-08-08       Impact factor: 4.466

Review 7.  Potential of Protein-based Anti-metastatic Therapy with Serpins and Inter α-Trypsin Inhibitors.

Authors:  Ulrich H Weidle; Fabian Birzele; Georg Tiefenthaler
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069

8.  Macromolecular diffusion and release from self-assembled beta-hairpin peptide hydrogels.

Authors:  Monica C Branco; Darrin J Pochan; Norman J Wagner; Joel P Schneider
Journal:  Biomaterials       Date:  2008-12-18       Impact factor: 12.479

9.  Rendering protein-based particles transiently insoluble for therapeutic applications.

Authors:  Jing Xu; Jin Wang; J Christopher Luft; Shaomin Tian; Gary Owens; Ashish A Pandya; Peter Berglund; Patrick Pohlhaus; Benjamin W Maynor; Jonathan Smith; Bolyn Hubby; Mary E Napier; Joseph M DeSimone
Journal:  J Am Chem Soc       Date:  2012-05-17       Impact factor: 15.419

10.  Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: covalent cross-linking via michael addition to tyrosine oxidation products.

Authors:  Riccardo Torosantucci; Olivier Mozziconacci; Victor Sharov; Christian Schöneich; Wim Jiskoot
Journal:  Pharm Res       Date:  2012-05-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.